Mirum rises 2.8% after FDA approves Atebrioz for rare bone disorder
The approval was based on a 63-patient study; Mirum expects to launch the drug in October.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.